Diabetic Nephropathy Clinical Trials
Here is the most popular medical study for diabetic nephropathy
Popular filter options for diabetic nephropathy trials
Diabetic Kidney Disease Clinical Trials
View 7 Diabetic Kidney Disease medical studies.
Behavioural Intervention
Basic Needs Navigation for Diabetic Kidney Disease
This trial will test a basic needs navigation intervention to see if it can help low-income African Americans with diabetic kidney disease who are experiencing multidimensional adversity. The study will look at feasibility, clinical outcomes, self-care behaviors, and quality of life.
Fibrate
Fenofibrate for Type 1 Diabetes
This trial is to test whether the generic drug fenofibrate can prevent kidney damage in people with type 1 diabetes. 40 participants will be enrolled and given either fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and end of the study.
Procedure
Metabolic Surgery for Type 2 Diabetes
This trial is testing whether or not a vertical sleeve gastrectomy, a type of weight loss surgery, can help improve Type 2 diabetes in youth by looking at changes in things like insulin resistance, glycemic control, beta-cell function, and cardiovascular health.
Tetracycline Antibiotic
Minocycline for Diabetic Kidney Disease
Diabetic kidney disease increases the risk of illness and death from heart disease in patients with Type 2 diabetes. Some blood pressure medications called ACE inhibitors and ARBs slow progression of kidney disease, but the dose that can be used is often limited by side effects that are experienced by patients. The most limiting side effects of the current treatments are lowering of the kidney function or blood pressure, and a rise in blood potassium levels. A safe and inexpensive medication that doesn't lower kidney function or blood pressure or raise serum potassium would be useful. Minocycline is a tetracycline antibiotic with recently appreciated protective properties. In a published journal article by Dr. Isermann, minocycline prevented the death of specialized kidney cells in mice. The kidneys of these mice did not develop diabetic kidney disease when seen under the microscope and the mice experienced only a little bit of protein loss in the urine. In a different published paper, the authors showed that minocycline also decreased kidney injury in a model of non-diabetic kidney disease. A related tetracycline antibiotic was shown to lower urine protein in diabetic patients. These data support a rationale for testing to see if minocycline is safe and helpful in patients with diabetic kidney disease. In this study, all patients will stay on their usual medications for the treatment of diabetic kidney disease. Patients will be given either minocycline (100 mg by mouth twice a day for 24 weeks) or placebo (an inactive capsule taken twice a day for 24 weeks). Minocycline or placebo will be assigned by a process called "randomization", which is like a coin toss. Neither the patient nor the study team will know if the patient is taking placebo or minocycline until the end of the study. The study will assess minocycline safety and test to see if minocycline is helpful or not helpful for the treatment of diabetic kidney disease. This study was funded by the American Diabetes Association and is not supported by any pharmaceutical company.
DKD Clinical Trials
View 7 DKD medical studies.
Behavioural Intervention
Basic Needs Navigation for Diabetic Kidney Disease
This trial will test a basic needs navigation intervention to see if it can help low-income African Americans with diabetic kidney disease who are experiencing multidimensional adversity. The study will look at feasibility, clinical outcomes, self-care behaviors, and quality of life.
Fibrate
Fenofibrate for Type 1 Diabetes
This trial is to test whether the generic drug fenofibrate can prevent kidney damage in people with type 1 diabetes. 40 participants will be enrolled and given either fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and end of the study.
Procedure
Metabolic Surgery for Type 2 Diabetes
This trial is testing whether or not a vertical sleeve gastrectomy, a type of weight loss surgery, can help improve Type 2 diabetes in youth by looking at changes in things like insulin resistance, glycemic control, beta-cell function, and cardiovascular health.
Tetracycline Antibiotic
Minocycline for Diabetic Kidney Disease
Diabetic kidney disease increases the risk of illness and death from heart disease in patients with Type 2 diabetes. Some blood pressure medications called ACE inhibitors and ARBs slow progression of kidney disease, but the dose that can be used is often limited by side effects that are experienced by patients. The most limiting side effects of the current treatments are lowering of the kidney function or blood pressure, and a rise in blood potassium levels. A safe and inexpensive medication that doesn't lower kidney function or blood pressure or raise serum potassium would be useful. Minocycline is a tetracycline antibiotic with recently appreciated protective properties. In a published journal article by Dr. Isermann, minocycline prevented the death of specialized kidney cells in mice. The kidneys of these mice did not develop diabetic kidney disease when seen under the microscope and the mice experienced only a little bit of protein loss in the urine. In a different published paper, the authors showed that minocycline also decreased kidney injury in a model of non-diabetic kidney disease. A related tetracycline antibiotic was shown to lower urine protein in diabetic patients. These data support a rationale for testing to see if minocycline is safe and helpful in patients with diabetic kidney disease. In this study, all patients will stay on their usual medications for the treatment of diabetic kidney disease. Patients will be given either minocycline (100 mg by mouth twice a day for 24 weeks) or placebo (an inactive capsule taken twice a day for 24 weeks). Minocycline or placebo will be assigned by a process called "randomization", which is like a coin toss. Neither the patient nor the study team will know if the patient is taking placebo or minocycline until the end of the study. The study will assess minocycline safety and test to see if minocycline is helpful or not helpful for the treatment of diabetic kidney disease. This study was funded by the American Diabetes Association and is not supported by any pharmaceutical company.
Frequently Asked Questions
Introduction to diabetic nephropathy
What are the top hospitals conducting diabetic nephropathy research?
In the realm of diabetic nephropathy, several top hospitals are leading the charge in clinical trials and research. Milwaukee's Medical College of Wisconsin is actively conducting one trial focused on this condition, with a total of three trials to their credit thus far. Their dedication to advancing understanding and treatment options for diabetic nephropathy became evident when they recorded their first trial in 2022. Similarly, in Boston, the renowned Joslin Diabetes Center has not only undertaken one active clinical trial but also boasts an impressive history of five past trials related to diabetic nephropathy since embarking on their pioneering investigation back in 1993.
Further contributing to the fight against this complex condition is the Brehm Center for Diabetes Research at the University of Michigan in Ann Arbor. With one ongoing trial underway and three previous investigations under its belt, this institution has been making significant strides since initiating its initial diabetic nephropathy study in 2014. In Burlington's Lahey Hospital and Medical Center, researchers are currently engaged in an active trial concerning diabetic nephropathy while marking their first recorded endeavor into exploring this area as recently as 2022.
Finally, SUNY Upstate Medical University located in Syracuse presents another vital player within this field by conducting one current clinical trial for diabetic nephropathy alongside three earlier studies conducted since launching their inaugural investigation back in 2014.
These hospitals' commitment to studying and treating complications arising from diabetes serves as a beacon of hope for patients suffering from conditions like diabetic nephropathy. Through innovative research practices and determined medical teams across various regions, we inch ever closer towards better management strategies and improved patient outcomes.
Which are the best cities for diabetic nephropathy clinical trials?
When it comes to clinical trials for diabetic nephropathy, several cities have emerged as leaders in research. Milwaukee, Wisconsin; Boston, Massachusetts; Ann Arbor, Michigan; Burlington, Massachusetts; and Syracuse, New york each offer 1 active trial studying treatments like Intervention Group or Fenofibrate. These cities provide individuals with access to cutting-edge research opportunities aimed at advancing the understanding and management of diabetic nephropathy.
Which are the top treatments for diabetic nephropathy being explored in clinical trials?
Clinical trials are exploring various treatments for diabetic nephropathy, a complication of diabetes that affects the kidneys. Two standout options being investigated include fenofibrate and allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion. Fenofibrate, introduced in 2016, is currently under investigation in one active trial specifically targeting diabetic nephropathy among its three total trials. Another promising treatment is the single infusion of allogeneic adipose-derived MSCs, which entered the clinical trial scene in 2021 and is being studied in one ongoing trial dedicated to diabetic nephropathy. These innovative approaches hold significant potential for improving outcomes for individuals with this condition.
What are the most recent clinical trials for diabetic nephropathy?
Recent clinical trials offer promising advancements in the treatment of diabetic nephropathy, a serious complication of diabetes affecting the kidneys. One notable trial focuses on the use of fenofibrate, which has shown potential benefits in managing this condition during its Phase 2 study. Additionally, allogeneic adipose-derived mesenchymal stem cells (MSC) have demonstrated promise as a single infusion therapy for diabetic nephropathy patients in their Phase 1 trial. Furthermore, ongoing investigations are exploring various approaches to better understand and address this condition's complexities through combined Phase 1 and Phase 2 studies. Although earlier trials with thiamine and isolated pancreas transplants were conducted several years ago, they provide valuable insights into potential treatments for diabetic nephropathy. These recent clinical trials offer hope for improved outcomes and quality of life among individuals affected by this challenging disease.
What diabetic nephropathy clinical trials were recently completed?
Several noteworthy clinical trials investigating treatments for diabetic nephropathy have recently concluded, offering hope for patients with this condition. In April 2021, Boehringer Ingelheim completed a trial examining the efficacy of BI 685509 in managing diabetic nephropathy. Additionally, CSL Behring's study on CSL346 was finalized in September 2020 and AstraZeneca wrapped up their MEDI3506 trial in November 2019. These significant milestones represent important strides forward in our understanding and treatment of diabetic nephropathy, potentially leading to improved outcomes for those affected by this complication of diabetes.